Platform Advantage Trellis's CellSpot platform enables rapid discovery of native human monoclonal antibodies with high affinity to conserved bacterial epitopes, exemplified by TRL1068 targeting DNABII. This differentiates Trellis for licensing or co-development partnerships seeking a scalable source of elite antibodies for anti-biofilm applications.

Broad Biofilm Opportunity DNABII is a highly conserved target across Gram-positive and Gram-negative bacteria and is central to biofilm integrity; TRL1068's high affinity reduces biofilm persistence and resistance, creating a potentially large addressable market in drug-resistant infections for collaboration with pharma, hospitals, and ID-focused CROs.

Regulatory Leverage FDA Fast Track, QIDP, and Orphan Drug designations for TRL1068 provide regulatory incentives that can shorten development timelines and de-risk licensing discussions, making Trellis an attractive partner for downstream commercialization deals.

Investment Momentum Recent Nodenza Venture Partners investment in Trellis signals external validation and potential to unlock strategic partnerships, co-investment, or milestone-based financing to advance TRL1068 and related antibody programs.

Licensing Readiness With a focused clinical-stage program, a lean team, and headquarters in Redwood City, Trellis is well-positioned to pursue upfront licensing, collaboration agreements, or CRO/CMC partnerships to accelerate clinical development and market entry for anti-biofilm antibodies.